Clinical trial
Safety and Efficacy of Adalimumab in Patients With Moderate to Severely Active…
NCT00195689 · Abbott, Industry · Completed
Key facts
| NCT number | NCT00195689 |
|---|---|
| Title | Safety and Efficacy of Adalimumab in Patients With Moderate to Severely Active Psoriatic Arthritis |
| Official title | A Multi-Center Continuation Trial for Patients Completing Study M02-518 and M02-570 of the Human Anti-TNF Monoclonal Antibody Adalimumab (D2E7) in Patients With Moderate to Severely Active Psoriatic Arthritis |
| Lead sponsor | Abbott, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Psoriatic Arthritis |
| Intervention type | Biological |
| Interventions | Human anti-TNF monoclonal antibody/adalimumab |
| Enrollment | 400 |
| Start date | Aug 1, 2003 |
| First posted | Sep 20, 2005 |
| Last update posted | Aug 29, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: